Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

One out of the three major indices traded up today The three major indices are trading lower today with the

Dow Jones Industrial Average

(

^DJI

) trading down 5.41 points (0.0%) at 17,746 as of Thursday, July 30, 2015, 4:20 PM ET. The NYSE advances/declines ratio sits at 1,569 issues advancing vs. 1,503 declining with 140 unchanged.

The Drugs industry as a whole closed the day down 0.6% versus the S&P 500, which was unchanged. Top gainers within the Drugs industry included

BioPharmX

(

BPMX

), up 10.2%,

Cellectar Biosciences

(

CLRB

), up 7.5%,

Cyanotech

(

CYAN

), up 3.5%,

Aptose Biosciences

(

APTO

), up 1.7% and

Onconova Therapeutics

(

ONTX

), up 2.5%.

TheStreet Ratings Group would like to highlight 3 stocks pushing the industry higher today:

Onconova Therapeutics

(

ONTX

) is one of the companies that pushed the Drugs industry higher today. Onconova Therapeutics was up $0.05 (2.5%) to $2.08 on light volume. Throughout the day, 8,030 shares of Onconova Therapeutics exchanged hands as compared to its average daily volume of 34,300 shares. The stock ranged in a price between $2.03-$2.21 after having opened the day at $2.21 as compared to the previous trading day's close of $2.03.

Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule drug candidates to treat cancer. Onconova Therapeutics has a market cap of $44.9 million and is part of the health care sector. Shares are down 38.3% year-to-date as of the close of trading on Wednesday. Currently there are 2 analysts who rate Onconova Therapeutics a buy, no analysts rate it a sell, and 2 rate it a hold.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

TheStreet Ratings rates Onconova Therapeutics as a

sell

. The company's weaknesses can be seen in multiple areas, such as its disappointing return on equity and generally disappointing historical performance in the stock itself.

Highlights from TheStreet Ratings analysis on ONTX go as follows:

  • Return on equity has greatly decreased when compared to its ROE from the same quarter one year prior. This is a signal of major weakness within the corporation. Compared to other companies in the Biotechnology industry and the overall market, ONCONOVA THERAPEUTICS INC's return on equity significantly trails that of both the industry average and the S&P 500.
  • ONTX's stock share price has done very poorly compared to where it was a year ago: Despite any rallies, the net result is that it is down by 54.66%, which is also worse that the performance of the S&P 500 Index. Investors have so far failed to pay much attention to the earnings improvements the company has managed to achieve over the last quarter. Naturally, the overall market trend is bound to be a significant factor. However, in one sense, the stock's sharp decline last year is a positive for future investors, making it cheaper (in proportion to its earnings over the past year) than most other stocks in its industry. But due to other concerns, we feel the stock is still not a good buy right now.
  • The company, on the basis of net income growth from the same quarter one year ago, has significantly underperformed compared to the Biotechnology industry average, but is greater than that of the S&P 500. The net income increased by 33.9% when compared to the same quarter one year prior, rising from -$18.68 million to -$12.34 million.
  • ONTX, with its very weak revenue results, has greatly underperformed against the industry average of 22.0%. Since the same quarter one year prior, revenues plummeted by 74.5%. The declining revenue has not hurt the company's bottom line, with increasing earnings per share.
  • ONCONOVA THERAPEUTICS INC has improved earnings per share by 34.5% in the most recent quarter compared to the same quarter a year ago. This company has reported somewhat volatile earnings recently. But, we feel it is poised for EPS growth in the coming year. During the past fiscal year, ONCONOVA THERAPEUTICS INC reported poor results of -$2.95 versus -$2.29 in the prior year. This year, the market expects an improvement in earnings (-$2.08 versus -$2.95).

You can view the full analysis from the report here:

Onconova Therapeutics Ratings Report

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

At the close,

Aptose Biosciences

(

APTO

) was up $0.08 (1.7%) to $4.41 on light volume. Throughout the day, 1,571 shares of Aptose Biosciences exchanged hands as compared to its average daily volume of 14,800 shares. The stock ranged in a price between $4.30-$4.41 after having opened the day at $4.31 as compared to the previous trading day's close of $4.34.

Aptose Biosciences has a market cap of $53.3 million and is part of the health care sector. Shares are down 24.7% year-to-date as of the close of trading on Wednesday.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Cellectar Biosciences

(

CLRB

) was another company that pushed the Drugs industry higher today. Cellectar Biosciences was up $0.23 (7.5%) to $3.29 on light volume. Throughout the day, 6,319 shares of Cellectar Biosciences exchanged hands as compared to its average daily volume of 14,200 shares. The stock ranged in a price between $3.08-$3.29 after having opened the day at $3.08 as compared to the previous trading day's close of $3.06.

Cellectar Biosciences has a market cap of $23.4 million and is part of the health care sector. Shares are up 0.3% year-to-date as of the close of trading on Wednesday.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.